title: An Audit of medical thoracoscopy and talc poudrage for pneumothorax prevention in advanced COPD.
abstract: OBJECTIVE
  To prospectively study all patients with COPD and spontaneous pneumothorax (SP) who underwent thoracoscopic talc poudrage (TP) under local anesthesia to determine its efficacy and safety in recurrence prevention.
  
  
  METHODS
  Data on clinical measurements, complications, duration of chest tube drainage, length of hospital stay, and outcome were collected.
  
  
  RESULTS
  Forty-one patients (38 men and 3 women) with a mean (+/- SD) age of 70.7 +/- 7.2 years were treated. All patients had COPD, with a mean FEV(1) of 41 +/- 14% predicted. The majority of SPs measured 20 to 50% in size, and 34% were recurrent. Three grams of talc were insufflated into the pleural cavity without complications. Thirteen patients (32%) complained of pain, 5 (12%) developed fever, 27 (66%) had subcutaneous emphysema, and 7 (17%) had prolonged air leaks. Postoperative chest tube drainage and hospital stay were 4 and 5 days, respectively. Success was 95% after a median follow-up of 35 months. Four patients with FEV(1) of < 40% predicted died within 30 days of the procedure, yielding a mortality rate of 10%. FEV(1) (in liters), FEV(1) (in % predicted), and ischemic heart disease were risk factors that influenced early mortality.
  
  
  CONCLUSIONS
  Thoracoscopic TP is effective for pneumothorax prevention and can be performed with acceptable mortality in patients with advanced COPD.
authors.affiliation: Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore. gm3lp@sgh.com.sg
authors.forename: Pyng
authors.initials: P
authors.lastname: Lee
authors.forename: Wee See
authors.initials: WS
authors.lastname: Yap
authors.forename: Wee Yang
authors.initials: WY
authors.lastname: Pek
authors.forename: Alan Wei Keong
authors.initials: AW
authors.lastname: Ng
mesh_terms: D000368:Aged; D004322:Drainage; D005260:Female; D006801:Humans; D007902:Length of Stay; D008297:Male; D008485:Medical Audit; D017202:Myocardial Ischemia / Q000150:complications; D018700:Pleurodesis / Q000379:methods*; D011030:Pneumothorax / Q000401:mortality / Q000517:prevention & control*; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications*; D012008:Recurrence; D012449:Safety; D013627:Talc / Q000008:administration & dosage*; D013906:Thoracoscopy; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D013627:Talc